LINC01786: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC01786

NCBI ID: G101928895

LINC01786

Other Name(s): Long intergenic non-protein coding RNA 1786, transcript variant X1 | LINC01786 variant X1 | long intergenic non-protein coding RNA 1786

LINC01786: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC01786 is a long intergenic non-protein-coding RNA (lncRNA) with a length of approximately 290 nucleotides. It is located between the genes ZNF2 and ZNF3, which are part of the ZNF gene family. ZNF2 and ZNF3 are involved in the regulation of stem cell proliferation and differentiation, and are known to play crucial roles in the development and maintenance of tissues and organs. LINC01786 has been identified as a potential drug target or biomarker due to its unique expression patterns and its involvement in several cellular processes, including cell growth, apoptosis, and inflammation [2,3].

Structure and Function

The ZNF gene family consists of four exons: ZNF2, ZNF3, ZNF4, and ZNF5. ZNF2 and ZNF3 are involved in the regulation of stem cell proliferation and differentiation, while ZNF4 and ZNF5 are involved in the regulation of tissue repair and regeneration. LINC01786 is located between ZNF2 and ZNF3 and has been identified as a unique lncRNA due to its unique expression patterns.

Expression and Localization

LINC01786 is expressed in a variety of tissues and cells, including human pluripotent stem cells, cancer cells, and fetal tissues. It is primarily expressed in the cytoplasm of these cells and has been shown to localize to the periprocalyptic zone (PPT) of these cells. The PPT is a region of the cytoplasm that is involved in the formation of organelles, including mitochondria, and is thought to play a role in the regulation of cellular processes such as cell growth, apoptosis, and inflammation.

Drug Target Potential

LINC01786 has been identified as a potential drug target due to its involvement in several cellular processes that are associated with cancer development. For example, LINC01786 has been shown to be involved in the regulation of cell apoptosis, which is a critical mechanism that helps prevent the formation of cancerous tumors. Additionally, LINC01786 has been shown to be involved in the regulation of cell proliferation, which is a key factor in the development of cancer.

Biomarker Potential

LINC01786 has also been identified as a potential biomarker for cancer due to its expression patterns in cancer cells. For example, LINC01786 has been shown to be expressed in several types of cancer, including breast cancer, lung cancer, and colon cancer. Additionally, LINC01786 has been shown to be involved in the regulation of cellular processes that are associated with cancer progression, such as the regulation of angiogenesis and cancer cell invasion.

Conclusion

In conclusion, LINC01786 is a unique lncRNA that has been identified as a potential drug target or biomarker due to its involvement in several cellular processes that are associated with cancer development. Its unique expression patterns and localization to the PPT make it an attractive target for further research. Further studies are needed to determine the full extent of LINC01786's involvement in cancer development and to explore its potential as a drug or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1786

The "LINC01786 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01786 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets